Cargando…

A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia

BACKGROUND: Human T-Lymphotropic Virus type 1 (HTLV-1) is endemic among people of Melanesian descent in Papua New Guinea, Solomon Islands and Vanuatu, and in Indigenous populations from Central Australia. Molecular studies revealed that these Australo-Melanesian strains constitute the highly diverge...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassar, Olivier, Charavay, Françoise, Touzain, Frédéric, Jeannin, Patricia, Grangeon, Jean-Paul, Laumond, Sylvie, Chungue, Eliane, Martin, Paul M. V., Gessain, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245899/
https://www.ncbi.nlm.nih.gov/pubmed/28060812
http://dx.doi.org/10.1371/journal.pntd.0005278
_version_ 1782496903001276416
author Cassar, Olivier
Charavay, Françoise
Touzain, Frédéric
Jeannin, Patricia
Grangeon, Jean-Paul
Laumond, Sylvie
Chungue, Eliane
Martin, Paul M. V.
Gessain, Antoine
author_facet Cassar, Olivier
Charavay, Françoise
Touzain, Frédéric
Jeannin, Patricia
Grangeon, Jean-Paul
Laumond, Sylvie
Chungue, Eliane
Martin, Paul M. V.
Gessain, Antoine
author_sort Cassar, Olivier
collection PubMed
description BACKGROUND: Human T-Lymphotropic Virus type 1 (HTLV-1) is endemic among people of Melanesian descent in Papua New Guinea, Solomon Islands and Vanuatu, and in Indigenous populations from Central Australia. Molecular studies revealed that these Australo-Melanesian strains constitute the highly divergent HTLV-1c subtype. New Caledonia is a French overseas territory located in the Southwest Pacific Ocean. HTLV-1 situation is poorly documented in New Caledonia and the molecular epidemiology of HTLV-1 infection remains unknown. OBJECTIVES: Studying 500 older adults Melanesian natives from New Caledonia, we aim to evaluate the HTLV-1 seroprevalence and to molecularly characterize HTLV-1 proviral strains. STUDY DESIGN: Plasma from 262 men and 238 females (age range: 60–96 years old, mean age: 70.5) were screened for anti-HTLV-1 antibodies by particle agglutination (PA) and indirect immunofluorescence assay (IFA). Serological confirmation was obtained using Western blot assay. DNAs were extracted from peripheral blood buffy coat of HTLV-1 seropositive individuals, and subjected to four series of PCR (LTR-gag; pro-pol; pol-env and tax-LTR). Primers were designed from highly common conserved regions of the major HTLV-1 subtypes to characterize the entire HTLV-1 proviral genome. RESULTS: Among 500 samples, 3 were PA and IFA positive. The overall seroprevalence was 0.6%. The DNA sample from 1 New Caledonian woman (NCP201) was found positive by PCR and the complete HTLV-1 proviral genome (9,033-bp) was obtained. The full-length HTLV-1 genomic sequence from a native woman from Vanuatu (EM5), obtained in the frame of our previous studies, was also characterized. Both sequences belonged to the HTLV-1c Australo-Melanesian subtype. The NCP201 strain exhibited 0.3% nucleotide divergence with the EM5 strain from Vanuatu. Furthermore, divergence reached 1.1% to 2.9% with the Solomon and Australian sequences respectively. Phylogenetic analyses on a 522-bp-long fragment of the gp21-env gene showed the existence of two major clades. The first is composed of strains from Papua New Guinea; the second includes strains from all neighboring archipelagos (Solomon, Vanuatu, New Caledonia), and Australia. Interestingly, this second clade itself is divided into two sub-clades: strains from Australia on one hand, and strains from Solomon Islands, Vanuatu and New Caledonia on the other hand. CONCLUSIONS: The HTLV-1 seroprevalence (0.6%) in the studied adult population from New Caledonia appears to be low. This seroprevalence is quite similar to the situation observed in Vanuatu and Solomon Islands. However it is very different to the one encountered in Central Australia. Taken together, these results demonstrated that Australo-Melanesia is endemic for HTLV-1 infection with a high diversity of HTLV-1c strains and a clear geographic clustering according to the island of origin of HTLV-1 infected persons.
format Online
Article
Text
id pubmed-5245899
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52458992017-02-17 A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia Cassar, Olivier Charavay, Françoise Touzain, Frédéric Jeannin, Patricia Grangeon, Jean-Paul Laumond, Sylvie Chungue, Eliane Martin, Paul M. V. Gessain, Antoine PLoS Negl Trop Dis Research Article BACKGROUND: Human T-Lymphotropic Virus type 1 (HTLV-1) is endemic among people of Melanesian descent in Papua New Guinea, Solomon Islands and Vanuatu, and in Indigenous populations from Central Australia. Molecular studies revealed that these Australo-Melanesian strains constitute the highly divergent HTLV-1c subtype. New Caledonia is a French overseas territory located in the Southwest Pacific Ocean. HTLV-1 situation is poorly documented in New Caledonia and the molecular epidemiology of HTLV-1 infection remains unknown. OBJECTIVES: Studying 500 older adults Melanesian natives from New Caledonia, we aim to evaluate the HTLV-1 seroprevalence and to molecularly characterize HTLV-1 proviral strains. STUDY DESIGN: Plasma from 262 men and 238 females (age range: 60–96 years old, mean age: 70.5) were screened for anti-HTLV-1 antibodies by particle agglutination (PA) and indirect immunofluorescence assay (IFA). Serological confirmation was obtained using Western blot assay. DNAs were extracted from peripheral blood buffy coat of HTLV-1 seropositive individuals, and subjected to four series of PCR (LTR-gag; pro-pol; pol-env and tax-LTR). Primers were designed from highly common conserved regions of the major HTLV-1 subtypes to characterize the entire HTLV-1 proviral genome. RESULTS: Among 500 samples, 3 were PA and IFA positive. The overall seroprevalence was 0.6%. The DNA sample from 1 New Caledonian woman (NCP201) was found positive by PCR and the complete HTLV-1 proviral genome (9,033-bp) was obtained. The full-length HTLV-1 genomic sequence from a native woman from Vanuatu (EM5), obtained in the frame of our previous studies, was also characterized. Both sequences belonged to the HTLV-1c Australo-Melanesian subtype. The NCP201 strain exhibited 0.3% nucleotide divergence with the EM5 strain from Vanuatu. Furthermore, divergence reached 1.1% to 2.9% with the Solomon and Australian sequences respectively. Phylogenetic analyses on a 522-bp-long fragment of the gp21-env gene showed the existence of two major clades. The first is composed of strains from Papua New Guinea; the second includes strains from all neighboring archipelagos (Solomon, Vanuatu, New Caledonia), and Australia. Interestingly, this second clade itself is divided into two sub-clades: strains from Australia on one hand, and strains from Solomon Islands, Vanuatu and New Caledonia on the other hand. CONCLUSIONS: The HTLV-1 seroprevalence (0.6%) in the studied adult population from New Caledonia appears to be low. This seroprevalence is quite similar to the situation observed in Vanuatu and Solomon Islands. However it is very different to the one encountered in Central Australia. Taken together, these results demonstrated that Australo-Melanesia is endemic for HTLV-1 infection with a high diversity of HTLV-1c strains and a clear geographic clustering according to the island of origin of HTLV-1 infected persons. Public Library of Science 2017-01-06 /pmc/articles/PMC5245899/ /pubmed/28060812 http://dx.doi.org/10.1371/journal.pntd.0005278 Text en © 2017 Cassar et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cassar, Olivier
Charavay, Françoise
Touzain, Frédéric
Jeannin, Patricia
Grangeon, Jean-Paul
Laumond, Sylvie
Chungue, Eliane
Martin, Paul M. V.
Gessain, Antoine
A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title_full A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title_fullStr A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title_full_unstemmed A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title_short A Novel Human T-lymphotropic Virus Type 1c Molecular Variant in an Indigenous Individual from New Caledonia, Melanesia
title_sort novel human t-lymphotropic virus type 1c molecular variant in an indigenous individual from new caledonia, melanesia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245899/
https://www.ncbi.nlm.nih.gov/pubmed/28060812
http://dx.doi.org/10.1371/journal.pntd.0005278
work_keys_str_mv AT cassarolivier anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT charavayfrancoise anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT touzainfrederic anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT jeanninpatricia anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT grangeonjeanpaul anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT laumondsylvie anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT chungueeliane anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT martinpaulmv anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT gessainantoine anovelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT cassarolivier novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT charavayfrancoise novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT touzainfrederic novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT jeanninpatricia novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT grangeonjeanpaul novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT laumondsylvie novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT chungueeliane novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT martinpaulmv novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia
AT gessainantoine novelhumantlymphotropicvirustype1cmolecularvariantinanindigenousindividualfromnewcaledoniamelanesia